HSP70

Overview

HSP70 refers to the 70-kDa heat shock protein family, a highly conserved group of molecular chaperones involved in protein folding, refolding of stress-denatured proteins, prevention of protein aggregation, and support of cellular proteostasis. In biomedical research, HSP70 is widely studied as a stress-response protein because its expression often increases under conditions such as heat shock, oxidative stress, inflammation, and other forms of cellular injury. It is also relevant to cancer biology, where altered HSP70 activity can support tumor cell survival and stress tolerance.

Beyond its intracellular chaperone function, HSP70 has been investigated as a target in extracellular and membrane-associated signaling contexts. In recent studies, it has been linked to tumor cell survival pathways, stress adaptation, and immunologic modulation. These roles make HSP70 of interest in oncology, regenerative biology, anti-aging research, and therapeutic development, including strategies that combine HSP70 targeting with CRISPR-Cas method, checkpoint inhibitor, or antibody-based approaches.

Focus of Latest Publications

Recent publications have examined HSP70 as a therapeutic target and biomarker across several experimental systems. In non-small cell lung cancer, pifithrin-μ was reported as efficacious by inhibiting heat shock protein 70, indicating that pharmacologic interference with HSP70 may reduce cancer cell stress tolerance. This study was published with an expression of concern, so the reported finding should be interpreted cautiously, but it reflects ongoing interest in HSP70 as a cancer target.

In melanoma-related research, extracellular HSP70 was targeted with decoy antibodies. The study reported that B cell expansion generated antibodies directed against HSP70 present on the surface of melanosomes, and that blocking extracellular HSP70 prevented self-signaling and inhibited melanoma cell survival. This work is notable because it focuses on a non-canonical, extracellular pool of HSP70 rather than only the intracellular chaperone function. The use of anti-HSP70 monoclonal antibodies in this context suggests a potential immunotherapeutic strategy, especially when considered alongside checkpoint inhibitor and human cytotoxic t cell responses.

HSP70 also appeared in studies outside oncology. In Nile tilapia, dietary supplementation with the hexane fraction of Ulva fasciata extract was associated with upregulation of HSP70 together with growth hormone receptor, insulin-like growth factor 1, myostatin, tumor necrosis factor alpha, FASN, and lipoprotein lipase. The authors reported improved growth performance, immune responses, and antioxidant status, with the best results at the highest tested dose. In this setting, HSP70 likely served as part of a broader stress-response and metabolic adaptation profile rather than as a direct therapeutic target.

In neurodegenerative and regenerative contexts, HSP70 was used as a canonical marker of cellular stress and protection. Human iPSC-derived exosomes were characterized by ExoView assays and western blotting, confirming expression of canonical markers including HSP70/90. This supports the use of HSP70 as a quality-control and identity marker in extracellular vesicle research. Separately, a translational study in young mice examined whether early-life irisin administration and physical exercise could modulate renal expression of Klotho and HSP70, described as hallmark genes of cellular protection and anti-aging. Here, HSP70 was treated as part of a protective renal response linked to exercise physiology.

HSP70 was also incorporated into advanced cancer engineering platforms. In head and neck squamous cell carcinoma, a NIR-II biomimetic nanoplatform used optogenetic CD274 editing, with Hsp70 upregulation helping trigger CRISPR/Cas9-mediated editing. In another cancer nanotherapy study, disruption of the CDK7-HSP70 stress axis was reported to lower the thermal resistance threshold, supporting the idea that HSP70 contributes to resistance against photothermal stress. Together, these studies position HSP70 as a stress-axis component that can be manipulated to improve therapeutic sensitivity.